Biological Products: Cellular Therapy and FDA Approved Products

被引:107
作者
Golchin, Ali [1 ]
Farahany, Tahereh Zarnoosheh [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Student Res Comm, Tehran, Iran
[2] Islamic Azad Univ, Med Branch Tehran, Sch Adv Technol Med, Dept Biol, Tehran, Iran
关键词
Approved drugs; Applications; Cellular therapy; Gene therapy; Stem cell; PROSTATE-CANCER; SIPULEUCEL-T; STEM-CELLS; CAR-T; TISAGENLECLEUCEL; TECHNOLOGY; CARTILAGE; SAFETY; REPAIR;
D O I
10.1007/s12015-018-9866-1
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The pace of advances in the world of science have created new opportunities and insights that give us new and more understanding of our nature and environment. Among the different fields of science, new medical sciences have drawn a great deal of attention among medical science researchers and the society. The hope for finding treatments for incurable diseases and further improvement of man's health is growing thanks to new medical technologies. Among the novel medical fields that have been extensively covered by medical and academic societies are cell therapy and gene therapy that are categorized under regenerative medicine. The present paper is an attempt to introduce the prospect of a curative cell-based therapy and new cellular and gene therapy drugs that have been recently approved by FDA (food and drug administration). Cellular and gene therapy are two very close fields of regenerative medicine and sciences which their targets and applications can be discussed together. What adds to the importance of this new field of science is the possibility to translate the hope for treatment of incurable diseases into actual treatments. What follows delves deeper into this new field of science and the drugs.
引用
收藏
页码:166 / 175
页数:10
相关论文
共 62 条
[1]   Hemacord approval may foreshadow regulatory creep for HSC therapies [J].
Allison, Malorye .
NATURE BIOTECHNOLOGY, 2012, 30 (04) :304-304
[2]  
[Anonymous], 2018, MED LETT DRUGS THER, V60, P99
[3]   A Review of Chronic Granulomatous Disease [J].
Arnold, Danielle E. ;
Heimall, Jennifer R. .
ADVANCES IN THERAPY, 2017, 34 (12) :2543-2557
[4]   FDA Approval of Tisagenlecleucel Promise and Complexities of a $475 000 Cancer Drug [J].
Bach, Peter B. ;
Giralt, Sergio A. ;
Saltz, Leonard B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (19) :1861-1862
[5]   Cell Therapy in Duchenne Muscular Dystrophy Treatment: Clinical Trials Overview [J].
Bajek, Anna ;
Porowinska, Dorota ;
Kloskowski, Tomasz ;
Brzoska, Edyta ;
Ciemerych, Maria A. ;
Drewa, Tomasz .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2015, 25 (01) :1-11
[6]  
Brenner M. K, 2018, SOMATIC GENE THERAPY, P225, DOI [10.1201/9781351076760-13, DOI 10.1201/9781351076760-13]
[7]   PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine [J].
Cheever, Martin A. ;
Higano, Celestia S. .
CLINICAL CANCER RESEARCH, 2011, 17 (11) :3520-3526
[8]   Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma [J].
Chesney, Jason ;
Awasthi, Sanjay ;
Curti, Brendan ;
Hutchins, Laura ;
Linette, Gerald ;
Triozzi, Pierre ;
Tan, Marcus C. B. ;
Brown, Russell E. ;
Nemunaitis, John ;
Whitman, Eric ;
Windham, Christopher ;
Lutzky, Jose ;
Downey, Gerald F. ;
Batty, Nicolas ;
Amatruda, Thomas .
MELANOMA RESEARCH, 2018, 28 (01) :44-51
[9]   Implementing a Program of Talimogene laherparepvec [J].
Collichio, Frances ;
Burke, Lauren ;
Proctor, Amber ;
Wallack, Diana ;
Collichio, Anthony ;
Long, Patricia K. ;
Ollila, David W. .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) :1828-1835
[10]  
Commissioner O, 2017, PRESS ANN FDA APPR C